Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 480

1.

Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.

Kabil N, Bayraktar R, Kahraman N, Mokhlis HA, Calin GA, Lopez-Berestein G, Ozpolat B.

Breast Cancer Res Treat. 2018 Oct;171(3):593-605. doi: 10.1007/s10549-018-4847-2. Epub 2018 Jul 3.

PMID:
29971628
2.

Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.

Bircan HA, Gurbuz N, Pataer A, Caner A, Kahraman N, Bayraktar E, Bayraktar R, Erdogan MA, Kabil N, Ozpolat B.

Lung Cancer. 2018 Oct;124:31-39. doi: 10.1016/j.lungcan.2018.07.027. Epub 2018 Jul 21.

PMID:
30268477
3.

Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B.

PLoS One. 2012;7(7):e41171. doi: 10.1371/journal.pone.0041171. Epub 2012 Jul 20.

4.
5.

MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.

Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A, Calin G, Lopez-Berestein G, Ozpolat B.

Oncotarget. 2017 Feb 14;8(7):11641-11658. doi: 10.18632/oncotarget.14264.

6.

Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.

Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B.

J Cell Mol Med. 2014 Nov;18(11):2235-51. doi: 10.1111/jcmm.12361. Epub 2014 Sep 12.

7.

Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.

Shahbazi R, Asik E, Kahraman N, Turk M, Ozpolat B, Ulubayram K.

Nanomedicine (Lond). 2017 Aug;12(16):1961-1973. doi: 10.2217/nnm-2017-0081. Epub 2017 Jul 26.

PMID:
28745127
8.

Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.

Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B.

Clin Cancer Res. 2018 Sep 1;24(17):4225-4241. doi: 10.1158/1078-0432.CCR-17-1959. Epub 2018 May 10.

9.

Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling.

Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam TG, Jeong BS, Kim JA.

Mol Cancer. 2016 Nov 21;15(1):75.

10.

Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.

Hamurcu Z, Delibaşı N, Geçene S, Şener EF, Dönmez-Altuntaş H, Özkul Y, Canatan H, Ozpolat B.

J Cancer Res Clin Oncol. 2018 Mar;144(3):415-430. doi: 10.1007/s00432-017-2557-5. Epub 2017 Dec 29.

PMID:
29288363
11.

Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.

Martin JL, Julovi SM, Lin MZ, de Silva HC, Boyle FM, Baxter RC.

Breast Cancer Res. 2017 Aug 4;19(1):90. doi: 10.1186/s13058-017-0882-x.

12.

microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.

Guo GC, Wang JX, Han ML, Zhang LP, Li L.

Cell Oncol (Dordr). 2017 Apr;40(2):157-166. doi: 10.1007/s13402-016-0312-6. Epub 2017 Jan 4.

PMID:
28054302
14.

Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.

Kim S, Lee J, Jeon M, Lee JE, Nam SJ.

Oncotarget. 2016 Jan 12;7(2):1544-58. doi: 10.18632/oncotarget.6441.

15.

MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.

Humphries B, Wang Z, Oom AL, Fisher T, Tan D, Cui Y, Jiang Y, Yang C.

Carcinogenesis. 2014 Oct;35(10):2254-63. doi: 10.1093/carcin/bgu133. Epub 2014 Jun 12.

16.

Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

Singel SM, Batten K, Cornelius C, Jia G, Fasciani G, Barron SL, Wright WE, Shay JW.

Breast Cancer Res. 2014 Mar 19;16(2):R28. doi: 10.1186/bcr3629.

17.

Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.

Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, Ozpolat B.

Apoptosis. 2014 Jan;19(1):241-58. doi: 10.1007/s10495-013-0927-2.

PMID:
24193916
18.

Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.

Shen Y, Zhang W, Liu J, He J, Cao R, Chen X, Peng X, Xu H, Zhao Q, Zhong J, Ding W, Lei X, Jiang Y, Zu X.

Int J Cancer. 2019 Feb 1;144(3):651-664. doi: 10.1002/ijc.31915. Epub 2018 Nov 7.

PMID:
30289981
19.

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.

Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.

Breast Cancer Res. 2015 Feb 22;17:25. doi: 10.1186/s13058-015-0527-x.

20.

The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.

Şakalar Ç, İzgi K, İskender B, Sezen S, Aksu H, Çakır M, Kurt B, Turan A, Canatan H.

Tumour Biol. 2016 Apr;37(4):4467-77. doi: 10.1007/s13277-015-4307-0. Epub 2015 Oct 26.

PMID:
26500095

Supplemental Content

Support Center